| gemlapodect (NOE-105) / Noema Pharma |
2021-004424-15: A study to evaluate different doses of a medicine called NOE-105 for the treatment of patients with Tourette Syndrome. |
|
|
| Not yet recruiting | 2 | 18 | Europe | NOE-105, Capsule | Noema Pharma Australia Pty Ltd, Noema Pharma Australia Pty Ltd | Tourette Syndrome, Facial and vocal tics, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05583955: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) |
|
|
| Completed | 2 | 75 | US, RoW | NOE-105, Escalating dose levels of NOE-105, Placebo, Placebo to match | Noema Pharma AG | Childhood-Onset Fluency Disorder | 10/23 | 11/23 | | |
| Not yet recruiting | 2 | 180 | NA | Gemlapodect, NOE-105, Placebo | Noema Pharma AG | Tourette Syndrome | 12/26 | 12/26 | | |
| basimglurant (NOE-101) / Noema Pharma |
2021-001866-39: An international randomized clinical study, measuring safety and effectiveness of basimglurant for the treatment of pain in patients with Trigeminal Neuralgia Estudio clínico aleatorizado internacional, que mide la seguridad y la eficacia del basimglurant para el tratamiento del dolor en pacientes con neuralgia del trigémino |
|
|
| Not yet recruiting | 2/3 | 200 | Europe | basimglurant, NOE-101, Capsule | Noema Pharma, Noema Pharma AG, Noema Pharma | Trigeminal neuralgia Neuralgia del trigémino, Trigeminal neuralgia is a chronic pain condition affecting the trigeminal nerve in the face causing sudden, severe facial pain. La Neuralgia del trigémino (NT) es un dolor crónico que afecta al nervio trigémino de la cara causando dolor facial repentino e intenso., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05217628: An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia. |
|
|
| Recruiting | 2/3 | 200 | Europe, US, RoW | Basimglurant, Placebo | Noema Pharma AG | Trigeminal Neuralgia | 01/25 | 01/26 | | |
2021-000838-34: Basimglurant in children, adolescents, and young adults with Tuberous Sclerosis Complex Basimglurant in bambini, adolescenti e giovani adulti affetti da complesso della sclerosi tuberosa. |
|
|
| Not yet recruiting | 2 | 67 | Europe | Basimglurant, [NOE-101], Capsule, hard | Noema Pharma AG, Noema Pharma, Noema Pharma AG, Noema Pharma | Tuberous Sclerosis Complex complesso della sclerosi tuberosa, Tuberous Sclerosis Complex is a genetic disorder of uncontrolled growth of numerous benign tumors in many parts of the body including the brain, and one of the leading genetic causes of epilepsy. È una malattia genetica caratterizzata dalla crescita incontrollata di numerosi tumori benigni in molte parti del corpo, compreso il cervello, ed è una delle principali cause genetiche dell'epilessia., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05059327: Basimglurant in Children, Adolescents, and Young Adults With TSC |
|
|
| Recruiting | 2 | 54 | Europe, US, RoW | Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant | Noema Pharma AG | Tuberous Sclerosis Complex | 11/24 | 01/26 | | |
